High-dose 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitro sou rea hydrochloride (ACNU) with autologous bone marrow rescue for patients with brain stem tumors.
T Hara, S Miyazaki, E Ishii, N Yoshida, K Inaba, K Ikeda, N Goya
{"title":"High-dose 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitro sou rea hydrochloride (ACNU) with autologous bone marrow rescue for patients with brain stem tumors.","authors":"T Hara, S Miyazaki, E Ishii, N Yoshida, K Inaba, K Ikeda, N Goya","doi":"10.1159/000120200","DOIUrl":null,"url":null,"abstract":"<p><p>4 patients with brain stem tumors were treated with high-dose ACNU with autologous bone marrow rescue. Hematologic and nonhematologic toxicities were not profound. There was objective evidence of response in 2 out of the 4. All were alive for 11-21 months from onset. Safe administration of high-dose ACNU with marrow rescue will warrant further control studies to determine its superiority over conventional doses.</p>","PeriodicalId":9836,"journal":{"name":"Child's brain","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000120200","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Child's brain","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000120200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7
Abstract
4 patients with brain stem tumors were treated with high-dose ACNU with autologous bone marrow rescue. Hematologic and nonhematologic toxicities were not profound. There was objective evidence of response in 2 out of the 4. All were alive for 11-21 months from onset. Safe administration of high-dose ACNU with marrow rescue will warrant further control studies to determine its superiority over conventional doses.